Yale NLP/LLM Interest Group Talks

Obesity, which affects nearly half of the U.S. population, is a leading contributor to morbidity and mortality, posing a critical public health challenge. While recent advancements in pharmacotherapy—particularly the use of the anti-obesity medication semaglutide—have shown promising results in clinical trials, questions remain about its effectiveness and economic impact in real-world settings.

In this session, Yuntian Liu will present findings from a study that assesses the clinical outcomes and healthcare expenditures associated with semaglutide across diverse patient populations. By analyzing electronic health record data from Sentara Healthcare and Yale New Haven Health Systems, the study examines the effects of semaglutide on weight, cardiovascular disease risk factors, and healthcare costs. The insights gained shed light on the long-term effectiveness and economic implications of semaglutide for obesity management and CVD prevention in routine clinical practice.